Recordati Raises Forecast for Isturisa After Smooth Launches
Peak Sales Estimate For Cushing's Drug Upped From €100m to €300-350m
Executive Summary
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.